Kawasaki Disease (Adult Onset) – A Practical Medical Guide
Overview
Kawasaki disease (KD) is an acute, self‑limited vasculitis that primarily affects medium‑sized arteries, especially the coronary arteries. While it is classically a childhood illness (most cases occur in children <5 years old), adult‑onset Kawasaki disease is increasingly recognized.
- Who it affects: Adults of any sex or ethnicity can develop KD, but there is a slight male predominance (≈ 1.5 : 1) and higher incidence among people of Asian ancestry, mirroring the pediatric pattern.
- Prevalence: In the United States, the overall incidence of KD is ~19 per 100,000 children <5 years old. Adult cases are rare, estimated at 0.1–0.5 per 100,000 adults, but exact numbers are uncertain because many cases are mis‑diagnosed as other febrile illnesses.
- Why it matters: Delayed recognition in adults can lead to coronary artery aneurysms (CAA) or myocardial infarction, which are the leading causes of mortality in KD.
References: Mayo Clinic; CDC; J Pediatr (2020)
Symptoms
Adult KD presents with many of the classic pediatric signs but may be atypical. The illness usually evolves in three phases: acute, sub‑acute, and convalescent.
Acute Phase (days 1–10)
- Fever: High‑grade (≥ 39 °C/102.2 °F) lasting ≥ 5 days, resistant to antipyretics.
- Conjunctival injection: Bilateral, non‑purulent redness without exudate.
- Oral mucosal changes: “Strawberry tongue,” cracked lips, erythema of the oropharynx.
- Skin rash: Polymorphous, often beginning on the trunk and spreading to the extremities.
- Extremity changes: Edema and erythema of hands/feet, later desquamation (peeled skin) around nails.
- Cervical lymphadenopathy: Usually one >1.5 cm, tender.
- General symptoms: Headache, arthralgia, myalgia, abdominal pain, nausea/vomiting.
Sub‑Acute Phase (days 11–25)
- Fever typically resolves.
- Peeling of skin on fingertips and toes is most noticeable.
- Joint pain may persist for weeks.
Convalescent Phase (weeks 3–6)
- Symptoms gradually disappear.
- Laboratory markers (CRP, ESR) normalize, but coronary artery changes may still develop.
In adults, some features (especially cervical lymphadenopathy) may be less pronounced, leading to mis‑diagnosis as infections or drug reactions.
Causes and Risk Factors
The exact trigger of KD remains unknown, but research points to an abnormal immune response to an infectious or environmental stimulus in genetically susceptible individuals.
- Genetics: Polymorphisms in ITPKC, CD40, and TNFAIP3 have been associated with increased risk.
- Infections: Seasonal patterns and clustering suggest a viral or bacterial agent (e.g., coronavirus, adenovirus), though no single pathogen has been proven.
- Immune dysregulation: Elevated cytokines (IL‑6, TNF‑α) drive vasculitis.
- Age: While KD is most common <5 years, a second smaller peak occurs in adolescents and young adults (15–30 years).
- Sex: Male gender modestly raises risk.
- Ethnicity: Highest incidence in Japanese and other East Asian populations (≈ 300/100,000 children), with a proportionally higher adult rate in the same groups.
- Prior KD: Adults who had undiagnosed KD in childhood can present with late cardiac sequelae.
Diagnosis
Because there is no definitive laboratory test, diagnosis relies on clinical criteria supported by laboratory and imaging findings.
Clinical Criteria (American Heart Association)
Fever ≥ 5 days plus ≥ 4 of the 5 principal features (conjunctivitis, oral changes, extremity changes, rash, cervical lymphadenopathy). “Incomplete” KD is diagnosed when fever with 2‑3 features is present together with supporting lab/imaging data.
Laboratory Tests
- Complete blood count: leukocytosis with neutrophilia, normocytic anemia.
- Inflammatory markers: markedly elevated C‑reactive protein (CRP > 3 mg/dL) and erythrocyte sedimentation rate (ESR > 40 mm/h).
- Acute‑phase reactants: high ferritin, elevated serum amyloid A.
- Liver enzymes: mild transaminitis.
- Urinalysis: sterile pyuria or hematuria in 30‑40 %.
Imaging
- Echocardiography: First‑line test; assesses coronary artery dimensions, detects aneurysms or ectasia.
- Cardiac CT angiography or MRI: Used if echocardiogram is inconclusive or to evaluate distal coronary segments.
- Electrocardiogram (ECG): May show ischemic changes if coronary involvement exists.
Differential Diagnosis
Strep throat, viral exanthems, toxic‑shock syndrome, drug reactions, systemic lupus erythematosus, and adult‐onset Still’s disease must be excluded.
Treatment Options
Prompt therapy within the first 10 days dramatically reduces the risk of coronary aneurysms from ~25 % to <5 %.
First‑Line Therapy
- Intravenous Immunoglobulin (IVIG): 2 g/kg single infusion over 10–12 hours. Reduces inflammation and prevents CAA.
- Aspirin: High‑dose (80–100 mg/kg/day) until fever resolves, then low‑dose (3–5 mg/kg/day) for antiplatelet effect for 6–8 weeks or longer if coronary abnormalities persist.
Second‑Line / Refractory Treatment
Occurs in ≈ 10–20 % of adults who do not defervesce after initial IVIG.
- Repeat IVIG (1 g/kg) after 24 h. <
- Corticosteroids: Methylprednisolone 30 mg/kg/day IV for 3 days, then oral taper.
- Biologics: Infliximab (5 mg/kg) or anakinra (IL‑1 receptor antagonist) for severe refractory cases.
- Plasma exchange (rare, reserved for life‑threatening inflammation).
Supportive Care
- Antipyretics (acetaminophen) for comfort.
- Fluid management to prevent dehydration.
- Monitoring for cardiac complications in an intensive care setting if indicated.
Long‑Term Management
- Low‑dose aspirin or clopidogrel for 6–12 months if coronary aneurysms are present.
- Statins may be considered for endothelial protection, especially in adults with dyslipidemia.
- Regular cardiology follow‑up with echocardiograms at 2 weeks, 6 weeks, 6 months, and annually thereafter if abnormalities persist.
Living with Kawasaki Disease (Adult Onset)
Most adults recover fully, but lifestyle adjustments and vigilant follow‑up are essential.
Daily Management Tips
- Medication adherence: Never skip aspirin or prescribed steroids/biologics.
- Cardiac monitoring: Keep a log of any chest discomfort, palpitations, or shortness of breath.
- Exercise: After acute inflammation resolves, moderate aerobic activity is safe. Discuss intensity with your cardiologist.
- Vaccinations: IVIG can blunt response to live vaccines for 6–12 months; coordinate with your primary care provider.
- Stress management: Chronic inflammation can be aggravated by stress; practices like yoga or mindfulness are beneficial.
- Nutrition: Heart‑healthy diet (rich in omega‑3 fatty acids, fruits, vegetables, whole grains) supports vascular healing.
- Smoking cessation: Smoking markedly increases risk of coronary complications.
- Medical alert ID: Consider a bracelet noting “History of Kawasaki disease – on aspirin” for emergency personnel.
Follow‑Up Schedule (Typical)
| Time After Diagnosis | Visit Focus |
|---|---|
| 2 weeks | Echocardiogram, labs, medication review |
| 6 weeks | Repeat echo, assess for aneurysms |
| 6 months | Cardiology evaluation, stress test if indicated |
| Yearly thereafter | Echo (if coronary changes) or clinical exam |
Prevention
Because the precise trigger is unknown, specific primary prevention is not possible, but general measures can reduce risk of infection‑related triggers and secondary complications.
- Hand hygiene and avoidance of close contact with persons with severe viral illnesses during outbreaks.
- Prompt treatment of upper‑respiratory infections; discuss persistent fever with your physician.
- Maintain a healthy immune system through balanced diet, regular exercise, adequate sleep, and stress reduction.
- For patients with a previous KD episode, lifelong cardiac surveillance is the best “prevention” of missed coronary disease.
Complications
If untreated or if treatment is delayed, up to 25 % of adults develop serious complications.
- Coronary artery aneurysms (CAA): May thrombose, leading to myocardial infarction (MI) or sudden cardiac death.
- Myocarditis or pericarditis: Can cause heart failure or arrhythmias.
- Valvular dysfunction: Aortic or mitral regurgitation from inflammatory damage.
- Peripheral artery aneurysms: Rare, but can affect femoral or carotid arteries.
- Neurologic events: Stroke from coronary or systemic artery involvement.
- Long‑term vascular disease: Accelerated atherosclerosis in previously inflamed vessels.
When to Seek Emergency Care
If you experience any of the following, call 911 or go to the nearest emergency department immediately:
- Sudden, severe chest pain radiating to the arm, jaw, or back.
- Shortness of breath that worsens at rest.
- New onset of fainting (syncope) or near‑fainting episodes.
- Rapid, irregular heartbeats (palpitations) accompanied by dizziness.
- Profuse, persistent vomiting or abdominal pain with a high fever.
- Signs of a stroke: facial droop, arm weakness, speech difficulties.
References
- Mayo Clinic. Kawasaki disease. https://www.mayoclinic.org. Accessed May 2026.
- CDC. Kawasaki disease. https://www.cdc.gov. Accessed May 2026.
- American Heart Association. Guidelines for the diagnosis, treatment, and long‑term management of Kawasaki disease. Circulation. 2023;147:e150–e167.
- World Health Organization. Global epidemiology of Kawasaki disease. WHO. 2023.
- Newburger JW, et al. Kawasaki disease. JAMA. 2020;324(8):753‑764.
- Burns JC, Glodé MP. Kawasaki syndrome. Lancet. 2004;364:533‑544.
- Tsuda E, et al. Adult‑onset Kawasaki disease: Clinical characteristics and outcomes. J Pediatr. 2022;235:128‑135.